rhythm Deltasync

Researchers evaluated Deltatonin® in BV-2 microglial cells, a laboratory model of immune cells in the brain, to investigate its effects on oxidative stress and antioxidant defence systems.

What did they find?

• Oxidative stress: Deltatonin® reduced reactive oxygen species (ROS) levels in the cell model.
• SOD activity: Levels of superoxide dismutase (SOD), an antioxidant defence enzyme, increased.
• Glutathione: Glutathione (GSH), an important component of the body's antioxidant defence system, also increased.

These findings suggest that Deltatonin® may influence cellular antioxidant responses under laboratory conditions.

Study details: In vitro study · BV-2 microglial cells · Assessment of ROS, SOD and GSH.

Researchers investigated longan flower water extract (LFWE) in mice, examining its effects on sleep duration, sleep latency and neurochemical markers involved in sleep regulation.

What did they find?

• Sleep duration: LFWE significantly prolonged sleep duration after 7 and 14 days of treatment.
• Melatonin levels: Circulating melatonin levels increased significantly after 14 days.
• Serotonin levels: Brain serotonin levels increased significantly, suggesting involvement of the serotonin to melatonin pathway.
• Dopamine levels: Brain dopamine levels also increased following treatment.
• Sleep onset: LFWE did not significantly reduce sleep latency in the study model.

These findings suggest that longan flower extract may influence sleep maintenance through changes in neurotransmitter and melatonin pathways.

Study details: Preclinical animal study · Male C57BL/6 mice, six per group · 25 mg/kg/day longan flower water extract · 7 or 14 days of treatment.

Researchers evaluated Deltatonin® Longan Flower Extract and its major phenolic compound, corilagin, to investigate their effects on genes involved in the melatonin and serotonin biosynthesis pathway.

What did they find?

• Pathway gene expression: Deltatonin® increased the expression of TPH1, DDC, AANAT and ASMT.
• Melatonin pathway: These genes are involved in the biochemical pathway connecting serotonin production with melatonin biosynthesis.
• Potential sleep relevance: The findings suggest a possible mechanism through which Deltatonin® may influence sleep related biological pathways.

These findings provide mechanistic evidence for Deltatonin®'s potential role in sleep regulation.

Study details: In vitro study · Gene expression analysis of TPH1, DDC, AANAT and ASMT.

Researchers investigated the effects of Deltatonin® on inflammatory signalling in BV-2 microglial cells by examining two markers associated with inflammatory responses: cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS).

What did they find?

• COX-2: Deltatonin® reduced COX-2 levels in the cell model.
• iNOS: Levels of iNOS also decreased following treatment.
• Inflammatory signalling: The findings suggest that Deltatonin® may influence inflammatory responses in these laboratory conditions.

These results provide preliminary mechanistic evidence of activity in a neural cell model.

Study details: In vitro study · BV-2 microglial cells · Assessment of COX-2 and iNOS levels.

Researchers conducted a preliminary self-controlled study involving five office workers aged 25 to 40 with sleep disturbances. Participants took 400 mg of Deltatonin® one hour before bedtime for 28 days. Sleep quality and insomnia symptoms were assessed using standardised questionnaires.

What did they find?

• Sleep quality: Pittsburgh Sleep Quality Index (PSQI) scores indicated a reported 55.2% improvement by day 3 and 60.6% by day 28.
• Insomnia symptoms: Athens Insomnia Scale scores decreased by 47% after 3 days and 69% after 28 days.
• Participant outcomes: The report stated that 80% of participants were relieved of insomnia symptoms by the end of the study.

These preliminary findings suggest potential benefits for sleep quality and insomnia symptoms.

Study details: Human pilot study · 5 office workers aged 25 to 40 with sleep disturbances · 400 mg daily, one hour before bedtime · 28 days · Self-controlled design · PSQI, Athens Insomnia Scale, blood serotonin and salivary melatonin assessments.

In a preliminary study, five office workers with sleep disturbances took 400 mg of Deltatonin® one hour before bedtime for 28 days. Researchers measured blood serotonin and salivary melatonin at baseline, day 3 and day 28.

What did they find?

• Blood serotonin: Levels increased to 1.17 times baseline by day 3 and 2.33 times baseline by day 28.
• Salivary melatonin: Levels increased to 2.21 times baseline by day 3 and 9.15 times baseline by day 28.
• Measurement period: Increases were reported during the 28 day supplementation period.

These findings suggest that Deltatonin® may influence serotonin and melatonin levels.

Study details: Human pilot study · 5 participants · 400 mg daily, one hour before bedtime · 28 days · Blood serotonin and salivary melatonin measured at days 0, 3 and 28.